Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cephalomannine is a naturally occurring **taxane diterpenoid** structurally related to paclitaxel, isolated from various Taxus (yew) species including Taxus yunnanensis and Taxus wallichiana[1][2][4][8][13][18]. It exhibits antitumor and antiproliferative activity by binding to and stabilizing microtubules, which inhibits their depolymerization[4][16]. This leads to arrested mitosis at the G2/M phase and renders it cytotoxic to rapidly dividing cells, particularly cancer cells[4][16]. Cephalomannine induces cell death and has shown potent inhibition of cell proliferation in vitro, with demonstrated activity against cancers including **glioblastoma** and leukemia, in part by promoting autophagy[3][7]. While closely related to paclitaxel, cephalomannine differs at the amide side chain and is considered a natural congener; it has historically been used in research with potential as a chemotherapeutic agent, but is not approved for clinical use in humans[3][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalomannine.